Why the UK is the best European market for mHealth
Doctors in the United Kingdom have an open and positive attitude about using new technologies and digital health offerings into patient treatments—resulting in the U.K. ranking above other EU countries for the best health app market.
A recent report conducted by research2guidance, in collaboration with HIMSS Europe, found that this perception accounted for the U.K. receiving 55 percent of the favored vote from respondents.
RELATED TOPIC: Is mHealth worth your venture capital investment?
The consecutive four countries ranked at the top for mobile health app companies in Europe included Denmark, Finland, Netherlands and Sweden.
The survey of 5,000 app developers, health care professionals and digital health practitioners also found that Germany and France have “enormous potential” because of their substantial investments in their doctors and hospitals. But, the rankings for digital health adoption in both of these countries were low, as they revealed that “these countries are more reluctant to embrace the digitalization of health care.”
Ralf Jahns, managing director at research2guidance, said, “The survey is now in its sixth year and the response this time has been overwhelming, becoming increasingly evident that the momentum around mHealth is growing at a rapid pace.”
The growth of connected care in Europe is projected to have a 19.2 percent CAGR for the next five years, according to Berg Insight. By then some 13.7 million Europeans will use some kind of connected care system.
RELATED TOPIC: TOP 10: Medical apps for doctors and physicians
“There is a strong need for solutions that enable social care and health care services to be delivered more cost-efficiently without compromising the quality of care,” Lars Kurkinen, Senior Analyst, Berg Insight said in a statement last year.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”